Avalanche and Lonza partner to manufacture high volumes of viral vectors
This article was originally published in Scrip
Executive Summary
Avalanche Biotechnologies in San Francisco and biologics manufacturer Lonza entered into a collaboration to produce adeno-associated viral (AAV) vectors for gene therapy at a scale that supports late stage development for Avalanche's age-related macular degeneration (AMD) therapy AVA-101 and for third-party companies.